Characterization of a new low‐dose 6‐hydroxydopamine model of Parkinson's disease in rat

Intrastriatal administration of 6‐hydroxydopamine (6‐OHDA) induces partial degeneration of the nigrostriatal pathway, mimicking the pathology of Parkinson's disease (PD). Setting up the partial lesion model can be challenging because a number of experimental settings can be altered. This study compares seven experimental settings in a single study on d‐amphetamine‐induced rotations, tyrosine hydroxylase (TH)‐positive neurites in the striatum, dopamine transporter (DAT)‐positive neurites in the striatum, and TH‐positive cells in the substantia nigra pars compacta (SNpc) in rats. Moreover, we validate a new algorithm for estimating the number of TH‐positive cells. We show that the behavior and immunoreactivity vary greatly depending on the injection settings, and we categorize the lesions as progressive, stable, or regressive based on d‐amphetamine‐induced rotations. The rotation behavior correlated with the degree of the lesion, analyzed by immunohistochemistry; the largest lesions were in the progressive group, and the smallest lesions were in the regressive group. We establish a new low‐dose partial 6‐OHDA lesion model in which a total of 6 μg was distributed evenly to three sites in the striatum at a 10° angle. The administration of low‐dose 6‐OHDA produced stable and reliable rotation behavior and induced partial loss of striatal TH‐positive and DAT‐positive neurites and TH‐positive cells in the SNpc. This model is highly suitable for neurorestoration studies in the search for new therapies for PD, and the new algorithm increases the efficacy for estimating the number of dopamine neurons. This study can be extremely useful for laboratories setting up the partial 6‐OHDA model. © 2016 Wiley Periodicals, Inc.

[1]  Y. Agid,et al.  Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra , 1996, Brain Research.

[2]  Y. Michotte,et al.  Reversible neurochemical changes mediated by delayed intrastriatal glial cell line‐derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model , 2009, The journal of gene medicine.

[3]  R. Burke,et al.  Striatal 6-hydroxydopamine induces apoptosis of nigral neurons in the adult rat , 2002, Brain Research.

[4]  J. O'Brien,et al.  Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. , 2012, Brain : a journal of neurology.

[5]  A. Granholm,et al.  6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat , 1996, Experimental Brain Research.

[6]  G. Wooten,et al.  Altered pharmacokinetics of L‐dopa metabolism in rat striatum deprived of dopaminergic innervation , 1984, Neurology.

[7]  P. Tuomainen,et al.  Different in vivo properties of three new inhibitors of catechol O‐methyltransferase in the rat , 1992, British journal of pharmacology.

[8]  U. Ungerstedt,et al.  6-Hydroxy-dopamine induced degeneration of central monoamine neurons. , 1968, European journal of pharmacology.

[9]  Greg A. Gerhardt,et al.  Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats , 1993, Brain Research.

[10]  L. Swanson The Rat Brain in Stereotaxic Coordinates, George Paxinos, Charles Watson (Eds.). Academic Press, San Diego, CA (1982), vii + 153, $35.00, ISBN: 0 125 47620 5 , 1984 .

[11]  M. Saarma,et al.  Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Neurorestorative in Rat Model of Parkinson's Disease , 2009, The Journal of Neuroscience.

[12]  A. Salgado,et al.  Behavioral characterization of the 6-hydroxidopamine model of Parkinson’s disease and pharmacological rescuing of non-motor deficits , 2013, Molecular Neurodegeneration.

[13]  A. Björklund,et al.  Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat , 1996, Neuroscience.

[14]  D. Togasaki,et al.  Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by instrastriatal injection of 6-hydroxydopamine , 1995, Neuroscience.

[15]  Anders Björklund,et al.  Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat , 1998, Experimental Neurology.

[16]  Y. Agid,et al.  Injection of 6-hydroxydopamine into the substantia nigra of the rat. II. Diffusion and specificity. , 1973, Brain research.

[17]  T. Robinson,et al.  Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis , 1986, Brain Research Reviews.

[18]  L. Butcher Degenerative processes after punctate intracerebral administration of 6-hydroxydopamine , 2005, Journal of Neural Transmission.

[19]  A. Herbet,et al.  Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system , 1976, Brain Research.

[20]  R. Faull,et al.  Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra. , 1969, Experimental neurology.

[21]  T. Robinson,et al.  Time course of recovery of extracellular dopamine following partial damage to the nigrostriatal dopamine system , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  Jos Prickaerts,et al.  Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway , 2002, Experimental Neurology.

[23]  R. Burke,et al.  Clinical progression in Parkinson disease and the neurobiology of axons , 2010, Annals of neurology.

[24]  K. Soliman,et al.  The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro , 2004, Brain Research.

[25]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[26]  A. Björklund,et al.  Studies on Neuroprotective and Regenerative Effects of GDNF in a Partial Lesion Model of Parkinson's Disease , 1997, Neurobiology of Disease.

[27]  L. Descarries,et al.  Quantification of the dopamine innervation in adult rat neostriatum , 1986, Neuroscience.

[28]  M. Saarma,et al.  Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease , 2013, Brain and behavior.

[29]  M. Horne,et al.  Axonal sprouting following lesions of the rat substantia nigra , 2000, Neuroscience.

[30]  D. C. Sterio The unbiased estimation of number and sizes of arbitrary particles using the disector , 1984, Journal of microscopy.

[31]  John L. Hudson,et al.  Conditioned apomorphine-induced turning in 6-OHDA-lesioned rats , 1994, Pharmacology Biochemistry and Behavior.

[32]  M. Saarma,et al.  Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease , 2011, Experimental Neurology.

[33]  M. Youdim,et al.  Mechanism of 6-hydroxydopamine neurotoxicity. , 1997, Journal of neural transmission. Supplementum.

[34]  C. Cunha,et al.  Induction of depressive-like behavior by intranigral 6-OHDA is directly correlated with deficits in striatal dopamine and hippocampal serotonin , 2014, Behavioural Brain Research.

[35]  A. Raasmaja,et al.  High correlation between in vivo [123I]β-CIT SPECT/CT imaging and post-mortem immunohistochemical findings in the evaluation of lesions induced by 6-OHDA in rats , 2013, EJNMMI Research.

[36]  Mark J. West,et al.  Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias , 1999, Trends in Neurosciences.

[37]  G. Nappi,et al.  Time‐course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6‐hydroxydopamine in the rat: new clues from an old model , 2007, The European journal of neuroscience.

[38]  R. Wurtman,et al.  Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization , 1980, Brain Research.

[39]  Gwang Lee,et al.  Formation of parkin aggregates and enhanced PINK1 accumulation during the pathogenesis of Parkinson's disease. , 2010, Biochemical and biophysical research communications.

[40]  E. Abercrombie,et al.  l‐3,4‐Dihydroxyphenylalanine‐Induced Dopamine Release in the Striatum of Intact and 6‐Hydroxydopamine‐Treated Rats: Differential Effects of Monoamine Oxidase A and B Inhibitors , 1994, Journal of neurochemistry.

[41]  W. H. Oertel,et al.  Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.

[42]  W. Pirker,et al.  Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts , 2014, Movement disorders : official journal of the Movement Disorder Society.

[43]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[44]  Robert E. Burke,et al.  Axon degeneration in Parkinson's disease , 2013, Experimental Neurology.

[45]  P. Kalivas,et al.  Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity , 1991, Brain Research Reviews.